DNA repair pathways in breast cancer: from mechanisms to clinical applications

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2023-06-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10549-023-06995-zPMID 37289340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression

  2023cited by this paper
• Relationship between polymorphisms in homologous recombination repair genes RAD51 G172T、XRCC2 & XRCC3 and risk of breast cancer: A meta-analysis

  2023cited by this paper
• Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy

  2023cited by this paper
• MiR-4521 perturbs FOXM1-mediated DNA damage response in breast cancer

  2023cited by this paper
• Dysregulated FOXM1 Signaling in the regulation of cancer stem cells.

  2022cited by this paper
• Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.

  2022cited by this paper
• Cell Cycle Regulation by Integrin-Mediated Adhesion

  2022cited by this paper
• Fisetin induces DNA double-strand break and interferes with the repair of radiation-induced damage to radiosensitize triple negative breast cancer cells

  2022cited by this paper
• Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells

  2022cited by this paper
• Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer

  2022cited by this paper
• RIP140 regulates POLK gene expression and the response to alkylating drugs in colon cancer cells

  2022cited by this paper
• Cell cycle disturbances in mucopolysaccharidoses: Transcriptomic and experimental studies on cellular models

  2022cited by this paper
• PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond

  2022cited by this paper
• H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models

  2022cited by this paper
• Synergy between inhibitors of two mitotic spindle assembly motors undermines an adaptive response

  2022cited by this paper
• RANK pathway in cancer: underlying resistance and therapeutic approaches

  2022cited by this paper
• Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

  2022cited by this paper
• Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug–drug interaction study

  2022cited by this paper
• Axillary ultrasound after neoadjuvant therapy reduces the false-negative rate of sentinel lymph node biopsy in patients with cytologically node-positive breast cancer

  2022cited by this paper
• Identification of a Novel Myc-Regulated Gene Signature for Patients with Kidney Renal Clear Cell Carcinoma

  2022cited by this paper
• Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors

  2022cited by this paper
• Chrysin impairs genomic stability by suppressing DNA double-strand break repair in breast cancer cells

  2022cited by this paper
• DNA Repair and Replication-Related Gene Signature Based on Tumor Mutation Burden Reveals Prognostic and Immunotherapy Response in Gastric Cancer

  2022cited by this paper
• Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients

  2022cited by this paper
• Breast cancer in the era of integrating “Omics” approaches

  2022cited by this paper
• Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors

  2022cited by this paper
• The role of DNA mismatch repair in immunotherapy of human cancer

  2022cited by this paper
• Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies

  2022cited by this paper
• Characterisation of the spectrum and genetic dependence of collateral mutations induced by translesion DNA synthesis

  2022cited by this paper
• DNA Damage Tolerance Pathways in Human Cells: A Potential Therapeutic Target

  2022cited by this paper
• Homologous recombination DNA repair gene RAD51, XRCC2 & XRCC3 polymorphisms and breast cancer risk in South Indian women

  2022cited by this paper
• Cooperation between Angiogenesis, Vasculogenesis, Chemotaxis, and Coagulation in Breast Cancer Metastases Development: Pathophysiological Point of View

  2022cited by this paper
• Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context.

  2022cited by this paper
• Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update.

  2022cited by this paper
• Signal pathways and precision therapy of small-cell lung cancer

  2022cited by this paper
• Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis

  2021cited by this paper
• FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair

  2021cited by this paper
• RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site

  2021cited by this paper
• Berberine as a promising natural compound for the treatment of periodontal disease: A focus on anti‐inflammatory properties

  2021cited by this paper
• Cell cycle control in cancer

  2021cited by this paper
• The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data.

  2021cited by this paper
• Homologous Recombination Subpathways: A Tangle to Resolve

  2021cited by this paper
• Inhibiting homologous recombination by targeting RAD51 protein.

  2021cited by this paper
• Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer

  2021cited by this paper
• A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.

  2021cited by this paper
• Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study

  2021cited by this paper
• New RAD51 Inhibitors to Target Homologous Recombination in Human Cells

  2021cited by this paper
• [Analysis of PARP inhibitors induced anemia in advanced and relapsed epithelial ovarian cancer].

  2021cited by this paper
• Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

  2021cited by this paper
• Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy

  2021cited by this paper
• Activation of the eIF2α/ATF4 axis drives triple-negative breast cancer radioresistance by promoting glutathione biosynthesis

  2021cited by this paper
• TNFR2: Role in Cancer Immunology and Immunotherapy

  2021cited by this paper
• Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?

  2021cited by this paper
• An Overview of PARP Inhibitors for the Treatment of Breast Cancer

  2021cited by this paper
• The overexpression of DNA repair genes in invasive ductal and lobular breast carcinomas: Insights on individual variations and precision medicine

  2021cited by this paper
• BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression

  2021cited by this paper
• Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials

  2021cited by this paper
• Repair of DNA Double-Strand Breaks by the Nonhomologous End Joining Pathway.

  2021cited by this paper
• CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer

  2020cited by this paper
• Rucaparib in patients presenting a metastatic breast cancer with Homologous Recombination De�ciency, without germline BRCA1/2 mutation

  2020cited by this paper
• Nanocarriers as an Emerging Platform for Cancer Therapy

  2020cited by this paper
• Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.

  2020cited by this paper
• PARP inhibitors in ovarian cancer: An overview of the practice‐changing trials

  2020cited by this paper
• Triple-negative breast cancer: promising prognostic biomarkers currently in development

  2020cited by this paper
• Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.

  2020cited by this paper
• Anti‐inflammatory and immune‐modulatory impacts of berberine on activation of autoreactive T cells in autoimmune inflammation

  2020cited by this paper
• Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.

  2020cited by this paper
• Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.

  2020cited by this paper
• When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.

  2020cited by this paper
• Gastrointestinal events with PARP inhibitors in cancer patients: A meta‐analysis of phase II/III randomized controlled trials

  2020cited by this paper
• Base excision repair and its implications to cancer therapy

  2020cited by this paper
• Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).

  2020cited by this paper
• Nano-based delivery systems for berberine: A modern anti-cancer herbal medicine.

  2020cited by this paper
• TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

  2020cited by this paper
• PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair.

  2020cited by this paper
• Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.

  2020cited by this paper
• Synthesis of disaccharide modified berberine derivatives and their anti-diabetic investigation in zebrafish using a fluorescence-based technology.

  2020cited by this paper
• PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches

  2020cited by this paper
• New Machine Learning Applications to Accelerate Personalized Medicine in Breast Cancer: Rise of the Support Vector Machines

  2020cited by this paper
• Fanconi Anemia Pathway: Mechanisms of Breast Cancer Predisposition Development and Potential Therapeutic Targets

  2020cited by this paper
• PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

  2020cited by this paper
• Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer

  2020cited by this paper
• One end to rule them all: Non-homologous end-joining and homologous recombination at DNA double-strand breaks

  2020cited by this paper
• The Anti-Cancer Mechanisms of Berberine: A Review

  2020cited by this paper
• ATM Expression Is Elevated in Established Radiation-Resistant Breast Cancer Cells and Improves DNA Repair Efficiency

  2020cited by this paper
• Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2020cited by this paper
• PARP Inhibitors & Prostate Cancer: To Infinity and Beyond BRCA.

  2020cited by this paper
• BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?

  2020cited by this paper
• PARP inhibition in treatment of pancreatic cancer

  2020cited by this paper
• Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China

  2019cited by this paper
• DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC.

  2019cited by this paper
• The Fanconi Anemia Pathway in Cancer.

  2019cited by this paper
• LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers

  2019cited by this paper
• Rucaparib: A Review in Ovarian Cancer

  2019cited by this paper
• FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer

  2019cited by this paper
• Novel carbohydrate modified berberine derivatives: synthesis and in vitro anti-diabetic investigation.

  2019cited by this paper
• Ultrasound microbubble-mediated CRISPR/Cas9 knockout of C-erbB-2 in HEC-1A cells

  2019cited by this paper
• XRCC4 c.1394G>T Single Nucleotide Polymorphisms and Breast Cancer Risk among Filipinos

  2019cited by this paper
• WWP2 ubiquitylates RNA polymerase II for DNA-PK-dependent transcription arrest and repair at DNA breaks

  2019cited by this paper
• Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation

  2019cited by this paper

• The Genetic Polymorphisms of DNA Repair Gene RAD51 and Their Role as a Predictive Biomarker for Breast Cancer Risk and Response to Radiotherapy in Iraqi Women.

  2026cites this paper
• Signaling pathway dysregulation in breast cancer

  2025cites this paper
• Role of MRE11 in DNA damage repair pathway dynamics and its diagnostic and prognostic significance in hereditary breast and ovarian cancer

  2025cites this paper
• Exploiting replication stress for synthetic lethality in MYC-driven cancers.

  2025cites this paper
• DNA damage repair-related methylated genes RRM2 and GAPDH are prognostic biomarkers associated with immunotherapy for lung adenocarcinoma

  2025cites this paper
• DeepCCDS: Interpretable Deep Learning Framework for Predicting Cancer Cell Drug Sensitivity through Characterizing Cancer Driver Signals

  2025cites this paper
• The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers

  2025cites this paper
• Artemis (DCLRE1C) Acts as a Target to Enhance Radiotherapy Response in Triple-Negative Breast Cancer

  2025cites this paper
• Analyzing the Mutational Landscape of Prostate Cancer Susceptibility Genes through Next-Generation Sequencing (NGS) Analysis

  2024cites this paper
• Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence.

  2024cites this paper
• DNA damage response in breast cancer and its significant role in guiding novel precise therapies

  2024influential citation
• Somatic gene mutations involved in DNA damage response/Fanconi anemia signaling are tissue- and cell-type specific in human solid tumors

  2024cites this paper
• Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours

  2024cites this paper
• Homologous recombination deficiency reflects the heterogeneity and monitoring treatment response for patients with breast cancer

  2023cites this paper
• Assessing the Phenotype of a Homologous Recombination Deficiency Using High Resolution Array-Based Comparative Genome Hybridization in Ovarian Cancer

  2023cites this paper
• Pyridazine Based Compounds with PARP-1 Inhibitory Activity

  2023cites this paper